← Back to Volume 6, Issue 7

Reproductive Endocrine Mechanisms Regulating Ovarian Reserve in Polyendocrine Metabolic Ovarian Syndrome

Yixin Feng
Vol.6, No.7, pp.49-54, 2026 DOI: 10.62051/ijphmr.v6n7.07 August 28, 2026
Download PDF
Abstract: This paper investigates the reproductive endocrine mechanisms of the ovarian reserve in polyendocrinopathy, autoimmune polyglandular syndrome type 1 (APCOS), which is a new term for polycystic ovary syndrome (PCOS). Rather than viewing ovarian reserve as a single number, the paper believes that the concept of reserve in PMOs should be understood through the interplay of follicle number, follicular arrest, granulosa-cell signalling, gonadotropin imbalance, androgen excess and metabolic disturbances. Based on the major consensus statements and endocrine studies, this essay will explore how disturbed hypothalamic-pituitary-ovarian signalling, functional ovarian hyperandrogenism, insulin-related dysregulation and anti-Mullerian hormone overproduction affect folliculogenesis and complicate the interpretation of ovarian reserve markers. PMOS also has a problem: although it appears to be in an overstocked state, it may not be ready to reproduce normally. Therefore, Ovarian Reserve Markers in PMOS should be considered in the context of the whole-body endocrine environment and not regarded as fixed indicators of ovulation potential.
Keywords: Polyendocrine metabolic ovarian syndrome, Ovarian reserve, Reproductive endocrinology, Anti-Mullerian hormone, Folliculogenesis, Hyperandrogenism
APA Citation: Yixin Feng (2026). Reproductive Endocrine Mechanisms Regulating Ovarian Reserve in Polyendocrine Metabolic Ovarian Syndrome. International Journal of Public Health and Medical Research, 6(7), 49-54. https://doi.org/10.62051/ijphmr.v6n7.07

References

  1. Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction, 19(1), 41–47.
  2. Azziz, R., Carmina, E., Dewailly, D., Diamanti Kandarakis, E., Escobar Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., & Witchel, S. F. (2006). Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. The Journal of Clinical Endocrinology & Metabolism, 91(11), 4237–4245.
  3. Teede, H. J., Khomami, M. B., Morman, R., Laven, J. S. E., Joham, A. E., Costello, M. F., Patil, M., Rees, D. A., Berry, L., Cree, M. G., Zhao, H., Norman, R. J., Dokras, A., Piltonen, T., & Global Name Change Consortium. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: A multistep global consensus process. The Lancet, 407(10545), 2329–2339.
  4. Franks, S. (1995). Polycystic ovary syndrome. The New England Journal of Medicine, 333(13), 853–861.
  5. Ehrmann, D. A. (2005). Polycystic ovary syndrome. The New England Journal of Medicine, 352(12), 1223–1236.
  6. La Marca, A., & Volpe, A. (2006). Anti Müllerian hormone (AMH) in female reproduction: Is measurement of circulating AMH a useful tool?. Clinical Endocrinology, 64(6), 603–610.
  7. Pellatt, L., Hanna, L., Brincat, M., Galea, R., Brain, H., Whitehead, S., & Mason, H. (2007). Granulosa cell production of anti Müllerian hormone is increased in polycystic ovaries. The Journal of Clinical Endocrinology & Metabolism, 92(1), 240–245.
  8. Dewailly, D., Andersen, C. Y., Balen, A., Broekmans, F., Dilaver, N., Fanchin, R., Griesinger, G., Kelsey, T. W., La Marca, A., Lambalk, C., Mason, H., Nelson, S. M., Visser, J. A., Wallace, W. H. B., & Anderson, R. A. (2014). The physiology and clinical utility of anti Müllerian hormone in women. Human Reproduction Update, 20(3), 370–385.
  9. Dumesic, D. A., Oberfield, S. E., Stener Victorin, E., Marshall, J. C., Laven, J. S. E., & Legro, R. S. (2015). Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocrine Reviews, 36(5), 487–525.
  10. Rosenfield, R. L., & Ehrmann, D. A. (2016). The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine Reviews, 37(5), 467–520.
  11. Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., Joham, A. E., & International PCOS Network. (2023). Recommendations from the 2023 international evidence based guideline for the assessment and management of polycystic ovary syndrome. European Journal of Endocrinology, 189(2), G43–G64.